Donald A. Barkauskas
About
Donald A. Barkauskas is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology.
According to data from OpenAlex, Donald A. Barkauskas has authored 79 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Pulmonary and Respiratory Medicine, 24 papers in Oncology and 18 papers in Molecular Biology. Recurrent topics in Donald A. Barkauskas's work include Sarcoma Diagnosis and Treatment (32 papers), Cancer Genomics and Diagnostics (12 papers) and Lymphoma Diagnosis and Treatment (12 papers). Donald A. Barkauskas is often cited by papers focused on Sarcoma Diagnosis and Treatment (32 papers), Cancer Genomics and Diagnostics (12 papers) and Lymphoma Diagnosis and Treatment (12 papers). Donald A. Barkauskas collaborates with scholars based in United States, Canada and Netherlands. Donald A. Barkauskas's co-authors include Razelle Kurzrock, Aaron M. Goodman, Shumei Kato, Andrew B. Sharabi, Vighnesh Walavalkar, Dewleen G. Baker, Caroline M. Nievergelt, Mark Krailo, Agorastos Agorastos and Richard Görlick and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.
In The Last Decade
Donald A. Barkauskas
78 papers receiving 3.1k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Donald A. Barkauskas United States | 27 | 1.2k | 972 | 823 | 494 | 395 | 79 | 3.1k | ||
| Premal H. Thaker United States | 39 | 1.8k 1.5× | 561 0.6× | 1.3k 1.6× | 570 1.2× | 354 0.9× | 283 | 5.5k | ||
| Feng Bi China | 33 | 1.6k 1.3× | 996 1.0× | 1.4k 1.7× | 1.0k 2.1× | 450 1.1× | 141 | 4.4k | ||
| Antonin Lévy France | 39 | 1.8k 1.5× | 1.8k 1.9× | 812 1.0× | 531 1.1× | 204 0.5× | 266 | 4.7k | ||
| Koen DeGeest United States | 34 | 1.5k 1.2× | 743 0.8× | 800 1.0× | 345 0.7× | 438 1.1× | 65 | 5.0k | ||
| Cristina Messa Italy | 45 | 553 0.5× | 2.5k 2.6× | 503 0.6× | 440 0.9× | 105 0.3× | 116 | 6.2k | ||
| Eli L. Diamond United States | 29 | 563 0.5× | 341 0.4× | 374 0.5× | 152 0.3× | 660 1.7× | 115 | 3.8k | ||
| Roland Bares Germany | 49 | 1.1k 0.9× | 2.0k 2.0× | 551 0.7× | 722 1.5× | 271 0.7× | 152 | 6.2k | ||
| Patrick J. Morrison United Kingdom | 37 | 485 0.4× | 455 0.5× | 1.1k 1.3× | 416 0.8× | 328 0.8× | 148 | 4.1k | ||
| Christos Christodoulou Greece | 25 | 1.1k 0.9× | 422 0.4× | 470 0.6× | 280 0.6× | 193 0.5× | 103 | 2.1k | ||
| Scott E. Smith United States | 31 | 2.1k 1.7× | 305 0.3× | 616 0.7× | 93 0.2× | 2.2k 5.6× | 113 | 4.6k |
Countries citing papers authored by Donald A. Barkauskas
Since
Specialization
Citations
This map shows the geographic impact of Donald A. Barkauskas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Donald A. Barkauskas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Donald A. Barkauskas more than expected).
Fields of papers citing papers by Donald A. Barkauskas
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Donald A. Barkauskas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Donald A. Barkauskas. The network helps show where Donald A. Barkauskas may publish in the future.
Co-authorship network of co-authors of Donald A. Barkauskas
This figure shows the co-authorship network connecting the top 25 collaborators of Donald A. Barkauskas. A scholar is included among the top collaborators of Donald A. Barkauskas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Donald A. Barkauskas. Donald A. Barkauskas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Wistinghausen, Birte, Donald A. Barkauskas, Lauren Saguilig, et al.. (2024). Durable immunity to EBV after rituximab and third-party LMP-specific T cells: a Children’s Oncology Group study. Blood Advances. 8(5). 1116–1127.
2.
Coffin, Cheryl M., R. Lor Randall, Donald A. Barkauskas, et al.. (2024). Clinical features and outcomes of young patients with low‐grade non‐rhabdomyosarcoma soft tissue sarcomas treated with a risk‐based strategy: A report from Children's Oncology Group study ARST0332. Pediatric Blood & Cancer. 71(8). e31062–e31062.
3.
Stieglitz, Elliot, Alex G. Lee, Steven P. Angus, et al.. (2024). Efficacy of the Allosteric MEK Inhibitor Trametinib in Relapsed and Refractory Juvenile Myelomonocytic Leukemia: a Report from the Children’s Oncology Group. Cancer Discovery. 14(9). 1590–1598.
4.
Stieglitz, Elliot, Alex Lee, Steven P. Angus, et al.. (2023). Efficacy of the Allosteric MEK Inhibitor Trametinib in Relapsed and Refractory Juvenile Myelomonocytic Leukemia: A Report from the Children's Oncology Group. Blood. 142(Supplement 1). 74–74.
5.
Xu, Gufeng, John Hicks, Manjula Nakka, et al.. (2023). The Role of FAS Receptor Methylation in Osteosarcoma Metastasis. International Journal of Molecular Sciences. 24(15). 12155–12155.
6.
Abbou, Samuel, Kelly Klega, Junko Tsuji, et al.. (2023). Circulating Tumor DNA Is Prognostic in Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group. Journal of Clinical Oncology. 41(13). 2382–2393.
7.
Alvarez, Elysia, Jiayi He, Sheri L. Spunt, et al.. (2022). Lymph node metastases in paediatric and young adult patients with non-rhabdomyosarcoma soft tissue sarcoma (NRSTS): Findings from Children's Oncology Group (COG) study ARST0332. European Journal of Cancer. 180. 89–98.
8.
Zhang, Xinyi, Shidan Wang, Erin R. Rudzinski, et al.. (2022). Deep Learning of Rhabdomyosarcoma Pathology Images for Classification and Survival Outcome Prediction. American Journal Of Pathology. 192(6). 917–925.
9.
Krishnamurthy, Nithya, Aaron M. Goodman, Donald A. Barkauskas, & Razelle Kurzrock. (2021). STK11 alterations in the pan-cancer setting: prognostic and therapeutic implications. European Journal of Cancer. 148. 215–229.
10.
Nikanjam, Mina, et al.. (2021). BRAF V600E/V600K Mutations versus Nonstandard Alterations: Prognostic Implications and Therapeutic Outcomes. Molecular Cancer Therapeutics. 20(6). 1072–1079.
11.
Riviere, Paul, Aaron M. Goodman, Ryosuke Okamura, et al.. (2020). High Tumor Mutational Burden Correlates with Longer Survival in Immunotherapy-Naïve Patients with Diverse Cancers. Molecular Cancer Therapeutics. 19(10). 2139–2145.
12.
Jahromi, Amin Haghighat, Donald A. Barkauskas, Matthew Zabel, et al.. (2020). Relationship between tumor mutational burden and maximum standardized uptake value in 2-[18F]FDG PET (positron emission tomography) scan in cancer patients. EJNMMI Research. 10(1). 150–150.
13.
Geller, James I., Joseph G. Pressey, Malcolm A. Smith, et al.. (2020). ADVL1522: A phase 2 study of lorvotuzumab mertansine (IMGN901) in children with relapsed or refractory wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor, or synovial sarcoma—A Children's Oncology Group study. Cancer. 126(24). 5303–5310.
14.
Mossé, Yaël P., Elizabeth Fox, David T. Teachey, et al.. (2019). A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921). Clinical Cancer Research. 25(11). 3229–3238.
15.
Kato, Shumei, Aaron M. Goodman, Vighnesh Walavalkar, et al.. (2017). Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate. Clinical Cancer Research. 23(15). 4242–4250.
16.
Li, Yiting, Manjula Nakka, Ching C. Lau, et al.. (2016). p27 Is a Candidate Prognostic Biomarker and Metastatic Promoter in Osteosarcoma. Cancer Research. 76(13). 4002–4011.
17.
Vo, Kieuhoa T., C. Lorrie Epling, Elizabeth Sinclair, et al.. (2016). Impact of Two Measures of Micrometastatic Disease on Clinical Outcomes in Patients with Newly Diagnosed Ewing Sarcoma: A Report from the Children's Oncology Group. Clinical Cancer Research. 22(14). 3643–3650.
18.
Yurgil, Kate A., Royce E. Clifford, Victoria B. Risbrough, et al.. (2015). Prospective Associations Between Traumatic Brain Injury and Postdeployment Tinnitus in Active-Duty Marines. Journal of Head Trauma Rehabilitation. 31(1). 30–39.
19.
Özcan, Süreyya, Donald A. Barkauskas, L. Renee Ruhaak, et al.. (2013). Serum Glycan Signatures of Gastric Cancer. Cancer Prevention Research. 7(2). 226–235.
20.
Meyers, Paul A., Holcombe E. Grier, Mark L. Bernstein, et al.. (2012). Phase II Trial of Trastuzumab in Combination With Cytotoxic Chemotherapy for Treatment of Metastatic Osteosarcoma With Human Epidermal Growth Factor Receptor 2 Overexpression: A Report From the Children's Oncology Group. Journal of Clinical Oncology. 30(20). 2545–2551.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Premal H. Thaker Breakdown of academic impact, for papers by Feng Bi Breakdown of academic impact, for papers by Antonin Lévy Breakdown of academic impact, for papers by Koen DeGeest Breakdown of academic impact, for papers by Cristina Messa Breakdown of academic impact, for papers by Eli L. Diamond Breakdown of academic impact, for papers by Roland Bares Breakdown of academic impact, for papers by Patrick J. Morrison Breakdown of academic impact, for papers by Christos Christodoulou Breakdown of academic impact, for papers by Scott E. Smith